Prelude Therapeutics (PRLD) reported second-quarter 2026 financial results, including revenue of $5.7 million and a net loss of $13.9 million, or $0.14 per share, for the three months ended June 30, 2026.
The company said cash, cash equivalents, restricted cash and marketable securities totaled $155.2 million as of June 30, 2026, with expected runway into the second quarter of 2028. Prelude also provided updates on its KAT6A degrader, JAK2V617F inhibitor and mCALR degrader antibody conjugate programs.
- R&D expense decreased to $16.1 million from $25.8 million in the prior-year period.
- G&A expense decreased to $5.0 million from $6.4 million a year earlier.
- Prelude expects to initiate a Phase 1 study of PRT13722 in HR+ breast cancer in the fourth quarter of 2026, pending IND clearance.
- Enrollment continues in the Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis.
- The company appointed Charles Morris, M.D., as chief medical officer in April 2026.
$PRLD Insider Trading Activity
$PRLD insiders have traded $PRLD stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $PRLD stock by insiders over the last 6 months:
- ADVISORS LLC ORBIMED has made 2 purchases buying 2,815,315 shares for an estimated $12,499,998 and 0 sales.
- DAVID P BONITA has made 2 purchases buying 2,815,315 shares for an estimated $12,499,998 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$PRLD Hedge Fund Activity
We have seen 40 institutional investors add shares of $PRLD stock to their portfolio, and 16 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 1,475,615 shares (+458.4%) to their portfolio in Q2 2026, for an estimated $7,865,027
- ECOR1 CAPITAL, LLC added 947,049 shares (+inf%) to their portfolio in Q1 2026, for an estimated $3,238,907
- KYNAM CAPITAL MANAGEMENT, LP added 803,684 shares (+101.9%) to their portfolio in Q1 2026, for an estimated $2,748,599
- PRICE T ROWE ASSOCIATES INC /MD/ removed 755,956 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $2,585,369
- SPHERA FUNDS MANAGEMENT LTD. added 435,587 shares (+354.9%) to their portfolio in Q1 2026, for an estimated $1,489,707
- STATE STREET CORP added 290,556 shares (+210.2%) to their portfolio in Q2 2026, for an estimated $1,548,663
- MILLENNIUM MANAGEMENT LLC added 231,740 shares (+153.5%) to their portfolio in Q1 2026, for an estimated $792,550
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
